Register for a live broadcast to learn more about TRODELVY (sacituzumab govitecan-hziy) with Dr. Hope S. Rugo

Study Finds More Genes Implicated in Breast and Ovarian Cancer Risk

Monday, July 10, 2017
For decades, the only genes tested for breast cancer risk were BRCA1 and BRCA2. Advances in genetic testing for hereditary cancer risk now enable clinicians to use multiple-gene panels to identify mutations. These panels have identified mutations in other cancer-associated genes in 5% to 15% of BRCA1/2-negative patients with suspected hereditary breast and ovarian cancer (HBOC) syndrome—more than doubling the mutation detection rate.

Researchers analyzed data from a commercial laboratory database of 95,561 women tested clinically for hereditary cancer risk with a 25-gene, next-generation sequencing panel. They accounted for family history and examined the association between pathogenic mutations and breast or ovarian cancer. A matched case-control analysis was conducted, defining cases as patients with breast or ovarian cancer and controls as women without cancer.

One or more pathogenic mutations were detected in 6775 (7%) of 95,561 women. Eight genes (ATMBARD1BRCA1BRCA2CHEK2PALB2PTEN, and TP53) were associated with breast cancer, with odds ratios ranging from two-fold to six-fold.

Eleven genes (ATMBRCA1BRCA2BRIP1MLH1MSH2MSH6NBNSTK11RAD51C, and RAD51D) were associated with ovarian cancer, with odds ratios ranging from two-fold to 40-fold. The researchers concluded that among the 95,561 women studied, 7% carried a pathogenic mutation in one or more cancer-associated genes. Associated breast and ovarian cancer risks ranged from two- to 40-fold after controlling for family history. They note that these results may better inform cancer risk counseling. The study findings are available here.

Talk about this article with nurses and others in the oncology community in the General Discussions Oncology Nursing News discussion group.
Lisa Schulmeister, MN, RN, ACNS-BC, FAAN
Blog Info
Lisa Schulmeister, MN, RN, ACNS-BC, FAAN is an oncology nursing consultant and editor-in-chief of Oncology Nursing News.
Author Bio
Lisa Schulmeister, MN, RN, ACNS-BC, FAAN, is the Editor-in-Chief for OncLive Nursing. She is an oncology nursing consultant and adjunct assistant professor of nursing at Louisiana State Health Sciences Center in New Orleans, LA. She provides continuing nursing education to nurses across the Unites States, is active in several professional nursing organizations, and is intrigued by the many ways nurses use technology to communicate.
External Resources

MJH Associates
American Journal of Managed Care
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
OncNurse Resources

Continuing Education
Web Exclusives

About Us
Advisory Board
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.